Institut Català de la Salut
Laboratori de Recerca Neurovascular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-09-09T08:15:55Z
2022-09-09T08:15:55Z
2022-04-29
Microhemorragias cerebrales; Beta-amiloidosis cerebral; Resonancia magnética preclínica
Cerebral microbleeds; Cerebral beta-amyloidosis; Preclinical MRI
Microhemorràgies cerebrals; Beta-amiloidosi cerebral; Ressonància magnètica preclínica
The pathological accumulation of parenchymal and vascular amyloid-beta (Aβ) are the main hallmarks of Alzheimer’s disease (AD) and Cerebral Amyloid Angiopathy (CAA), respectively. Emerging evidence raises an important contribution of vascular dysfunction in AD pathology that could partially explain the failure of anti-Aβ therapies in this field. Transgenic mice models of cerebral β-amyloidosis are essential to a better understanding of the mechanisms underlying amyloid accumulation in the cerebrovasculature and its interactions with neuritic plaque deposition. Here, our main objective was to evaluate the progression of both parenchymal and vascular deposition in APP23 and 5xFAD transgenic mice in relation to age and sex. We first showed a significant age-dependent accumulation of extracellular Aβ deposits in both transgenic models, with a greater increase in APP23 females. We confirmed that CAA pathology was more prominent in the APP23 mice, demonstrating a higher progression of Aβ-positive vessels with age, but not linked to sex, and detecting a pronounced burden of cerebral microbleeds (cMBs) by magnetic resonance imaging (MRI). In contrast, 5xFAD mice did not present CAA, as shown by the negligible Aβ presence in cerebral vessels and the occurrence of occasional cMBs comparable to WT mice. In conclusion, the APP23 mouse model is an interesting tool to study the overlap between vascular and parenchymal Aβ deposition and to evaluate future disease-modifying therapy before its translation to the clinic.
This work was funded by the Instituto de Salud Carlos III (ISCIII), (PI20/00465) and co-financed by the European Regional Development Fund (FEDER). The Neurovascular Research Laboratory is part of the RICORS-ICTUS-Enfermedades Vasculares Cerebrales network, ISCIII, Spain (RD21/0006/0007).
Article
Published version
English
Ratolins transgènics; Amiloïdosi; Malalties cerebrovasculars; ORGANISMS::Eukaryota::Animals::Animal Population Groups::Animals, Genetically Modified::Mice, Transgenic; DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebrovascular Disorders::Intracranial Arterial Diseases::Cerebral Arterial Diseases::Cerebral Amyloid Angiopathy; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Amyloid beta-Peptides; ORGANISMOS::Eukaryota::animales::grupos de población animal::animales modificados genéticamente::ratones transgénicos; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos cerebrovasculares::enfermedades arteriales intracraneales::enfermedades arteriales cerebrales::angiopatía amiloide cerebral; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::péptidos beta amiloides
MDPI
International Journal of Molecular Sciences;23(9)
https://doi.org/10.3390/ijms23094972
info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00465
info:eu-repo/grantAgreement/ES/PE2017-2020/RD21%2F0006%2F0007
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]